EUCTR2005-004676-20-NL进行中（未招募）不适用
A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Chemotherapy to the Efficacy of Chemotherapy Alone in Patients with Previously Treated Metastatic Colorectal Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically or cytologically-confirmed adenocarcinoma of the colon or rectum in patients who are presenting with metastatic disease
- •One and only one prior chemotherapy regimen for mCRC consisting of first-line fluoropyrimidine-based chemotherapy. (Prior adjuvant fluoropyrimidine-based
- •chemotherapy is allowed)
- •Radiographically documented disease progression per modified RECIST criteria either while receiving or = 6 months after the last dose of prior first-line fluoropyrimidine-based chemotherapy for mCRC
- •At least 1 uni-dimensionally measurable lesion of at least 20 mm per modified RECIST criteria. (All sites of disease must be evaluated = 28 days prior to enrollment)
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- •Paraffin-embedded tumor tissue from the primary tumor or metastasis available for central analyses of EGFr and biomarker testing
- •Man or woman = 18 years of age
- •Hematologic function, as follows (= 7 days of randomization):
- •o Absolute neutrophil count (ANC) = 1.5 x
- •o Platelet count = 100 x 109/L
- •o Hemoglobin = 9 g/dL
- •Renal function, as follows (= 7 days of randomization):
- •o Creatinine = 1.5 x upper limit of normal
- •Hepatic function, as follows (= 7 days of randomization):
- •o Aspartate aminotransferase (AST) = 3 x ULN (if liver metastases = 5 x ULN)
- •o Alanine aminotransferase (ALT) = 3 x ULN(if liver metastases = 5 x ULN)
- •o Total bilirubin = 1.5 x ULN
- •Metabolic function, as follows (= 7 days of randomization):
- •o Magnesium = lower limit of normal
- •Negative pregnancy test = 72 hours of randomization (females of childbearing
- •potential only)
- •Competent to comprehend, sign, and date an IEC/IRB-approved informed consent form
- •Life expectancy = 3 months
- •Are the trial subjects under 18?
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •History or known presence of central nervous system (CNS) metastases
- •History of another primary cancer, except:
- •o Curatively treated in situ cervical cancer, or
- •o Curatively resected non-melanoma skin cancer, or
- •o Other primary solid tumor curatively treated with no known active disease present and no treatment administered for = 5 years prior to randomization
- •Prior irinotecan therapy
- •Prior anti-EGFr antibody therapy (eg, cetuximab) or treatment with small molecule EGFr inhibitors (eg, erlotinib)
- •Systemic chemotherapy, hormonal therapy, immunotherapy or experimental or approved proteins/antibodies (eg, bevacizumab) = 30 days before randomization
- •Unresolved toxicities from prior systemic therapy that, in the opinion of the investigator, does not qualify the patient for randomization
- •Radiotherapy = 14 days prior to randomization. Patients must have recovered from all radiotherapy-related toxicities
- •Active infection requiring systemic treatment or any uncontrolled infection = 14 days prior to randomization
- •CYP3A4 enzyme inducing anti-convulsant medication (eg phenytoin, phenobarbital or carbamazepine), rifampin and rifabutin, and St. John’s Wort = 14 days before randomization
- •Ketoconazole = 7 days before randomization (Itraconazole should be used with caution)
- •Any investigational agent or therapy = 30 days before randomization
- •Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) = 1 year before randomization
- •Known allergy or hypersensitivity to irinotecan, 5-FU or leucovorin
- •History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest CT scan
- •Active inflammatory bowel disease or other bowel disease causing chronic diarrhea (defined as > CTC grade 2 [CTCAE version 3.0])
- •Known positive test(s) for human immunodeficiency virus (HIV) infection, hepatitis C
- •virus, acute or chronic active hepatitis B infection
- •Any co-morbid disease or condition that could increase the risk of toxicity (eg dihydropyrimidine deficiency, significant ascites or pleural effusion)
- •Any uncontrolled concurrent illness or history of any medical condition that may interfere with the interpretation of the study results
- •Major surgical procedure (requiring general anesthesia) = 28 days or minor surgical procedure (excluding central venous catheter placement) = 14 days before randomization. Patients must have recovered from surgery related toxicities
- •Subject who is pregnant or breast feeding
- •Woman or man of childbearing potential not consenting to use adequate contraceptive precautions ie. double barrier contraceptive methods (eg diaphragm plus condom), or abstinence during the course of the study and for 6 months after the last study drug administration for women, and 1 month for men
- •Subject unwilling or unable to comply with study requirements
- •Previously randomized into this study protocol
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Chemotherapy to the Efficacy of Chemotherapy Alone in Patients with Previously Treated Metastatic Colorectal CancerPatients with Previously Treated Metastatic Colorectal CancerEUCTR2005-004676-20-PTAmgen Inc.1,100
进行中（未招募）
不适用
A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Chemotherapy to the Efficacy of Chemotherapy Alone in Patients with Previously Treated Metastatic Colorectal CancerPatients with Previously Treated Metastatic Colorectal CancerEUCTR2005-004676-20-LTAmgen Limited1,100
进行中（未招募）
不适用
A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Chemotherapy to the Efficacy of Chemotherapy Alone in Patients with Previously Treated Metastatic Colorectal CancerPatients with Previously Treated Metastatic Colorectal CancerEUCTR2005-004676-20-IEAmgen Limited1,100
已完成
3 期
A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Chemotherapy to the Efficacy of Chemotherapy Alone in Patients with Previously Treated Metastatic Colorectal Cancermetastatic colorectal cancer1001799010017991NL-OMON29791Amgen50
进行中（未招募）
1 期
A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Chemotherapy to the Efficacy of Chemotherapy Alone in Patients with Previously Treated Metastatic Colorectal CancerEUCTR2005-004676-20-GBAmgen Limited1,100